We’re getting dizzy, what with all the healthcare reform stories whizzing past our heads these days. There’s so much going on, it’s hard to keep track of just where reform stands–and just where pharma stands within it. So, here for your perusal is a quick roundup of today’s developments….
If you’re a sales rep who needs another reason to cry into your soup, take a look at Reuters ‘ analysis of the earthquake that’s remodeling pharma sales . The short, short version: More sales cuts are yet to come, and smaller sales forces are here to stay. The…
Pfizer scored a court victory in the ongoing hormone-replacement litigation: A New York judge threw out lawsuits filed by 23 women who claimed that hormone replacement therapy had caused their breast cancer. In his ruling Justice Martin Shulman wrote, “[A] review of the material and the record as a…
OSI Pharmaceuticals got stiff-armed by an FDA advisory committee, which voted 12-1 against broadening use of its cancer drug Tarceva. The company had wanted to market the pill as a first-line maintenance treatment after chemotherapy. Currently, Tarceva is approved for use in lung cancer
GlaxoSmithKline published a list of fees paid between April 1 and June 30 to U.S. healthcare professionals for speaking and consulting services. GSK will update this list quarterly going forward.
Original Source of GSK publishes speaking, consulting fees paid to US healthcare professionals
Orchid Chemicals & Pharmaceuticals isn’t so different from the average American with lots of credit card debt. A big chunk of its income is earmarked to pay bills. The Indian drugmaker says it plans to pay off debt with the $400 million proceeds from the sale of its generic…
If you needed any more statistics showing that drug prices in the U.S. are higher than in the rest of the world, take a look at a new report from Britain’s Department of Health. In their 10th “state of the drug-pricing system” address to lawmakers, health officials compared pharma…
Well, there was a big reason why Bristol-Myers Squibb CFO Jean-Marc Huet wanted to go back to Europe : Consumer products giant Unilever hired him for the same job. Report
Original Source of Huet exiting Bristol for Unilever CFO post
The U.K.’s cost-effectiveness watchdog is back on duty, this time guarding the National Health Service’s pocketbook from Roche’s new arthritis drug RoActemra. The National Institute for Health and Clinical Excellence’s appraisal committee said it was inclined to reject RoActemra for NHS use–but that it might change its mind if…
The U.S. Senate’s flirtation